Glycogen synthase kinase-3 (GSK-3) and B-catenin: potential novel therapeutic targets for COPD
PhD ceremony: Mr. H.A. Baarsma, 16.15 uur, Academiegebouw, Broerstraat 5, Groningen
Dissertation: Glycogen synthase kinase-3 (GSK-3) and B-catenin: potential novel therapeutic targets for COPD
Promotor(s): prof. H. Meurs, prof. H.A.M. Kerstjens
Faculty: Mathematics and Natural Sciences
Hoeke Baarsma has demonstrated that both β-catenin and GSK-3 are important in specific cellular processes that contribute to the pathogenesis of COPD. Furthermore, he proposes that therapeutic intervention by GSK-3 inhibition may provide a novel therapeutic treatment for COPD.
Chronic obstructive pulmonary disease (COPD) is primarily caused by tobacco smoking and is characterized by a progressive decline of lung function. The persistent airflow limitation is the resultant of chronic inflammation and of structural alterations in the lungs, including airway remodeling and emphysema. Baarsma explored the functional roles of β-catenin and glycogen synthase kinase-3 (GSK-3), both critical effectors in the WNT-signaling pathway, in the pathological processes that underpin COPD.
Aberrant extracellular matrix (ECM) turnover is a pathological feature of COPD and contributes to the structural alterations in the lung. Baarsma demonstrated that activation of β-catenin contributes to ECM production by airway smooth muscle cells and pulmonary fibroblasts induced by the growth factor TGF-ß. Interestingly, this activation of the WNT pathway appeared enhanced in pulmonary fibroblasts of COPD patients. Moreover, the differentiation process of fibroblasts into more active myofibroblasts induced by TGF-β appeared dependent on both β-catenin and GSK-3. Further, the inflammatory response induced by exposure of airway smooth muscle cells to cigarette smoke appeared to be GSK-3 dependent.
Inhibition of GSK-3 protected against the ECM production and myofibroblast differentiation in lung fibroblasts. Moreover, in a guinea pig model of COPD GSK-3 inhibitors protected against airway fibrosis as well as extrapulmonary pathological features, such as right ventricle hypertrophy and skeletal muscle atrophy, which are similarly involved in COPD.
Last modified: | 13 March 2020 12.58 a.m. |
More news
-
17 June 2025
ERC Advanced grants for three UG researchers
The European Research Council has awarded ERC Advanced grants to Prof. Inga Kamp, Prof. Wouter Roos and Prof. Syuzanna Harutyunyan.
-
13 June 2025
Team 'Lord of the Roads' second at RDW Self Driving Challenge
The University of the North team 'Lord of the Roads', in which students from educational institutions Noorderpoort, Hanzehogeschool and the University of Groningen collaborated, came second in the RDW Self Driving Challenge (SDC). The team competed...
-
12 June 2025
Those most affected by modern agriculture
Farmers only grow a limited number of crops these days, which has significant consequences for the animals that live there. Raymond Klaassen researches what adjustments farmers could make to improve the conditions for the species most affected by...